Researchers at Weill Cornell Medicine have illuminated one of the important ways that cells respond to stress. The findings could also be relevant to Alzheimer’s, ALS and other diseases in which this mechanism may be abnormally active.
DNA can mimic protein functions by folding into elaborate, three-dimensional structures, according to a study from researchers at Weill Cornell Medicine and the National Heart, Lung, and Blood Institute, part of the National Institutes of Health.
An experimental contraceptive drug candidate developed by Weill Cornell Medicine investigators temporarily stops sperm in their tracks and prevents pregnancies in preclinical models.
Weill Cornell Medicine has been awarded a $1 million, three-year grant from the Department of Defense’s Kidney Cancer Research Program to fund research on the role of the protein ATF4 in clear cell renal cell carcinoma (ccRCC), a form of kidney cancer.
Six Weill Cornell Medicine postdoctoral associates, instructors and junior faculty seeking to pursue independent research careers have received 2022 JumpStart Career Development awards.
Dr. Sara Zaccara, a postdoctoral associate in the Department of Pharmacology at Weill Cornell Medicine, has won a 2022 Tri-Institutional Breakout Award for Junior Investigators.
The National Human Genome Research Institute has funded a multi-institutional Center of Excellence in Genome Sciences (CEGS), based at Weill Cornell Medicine, to develop new tools to study the major product of the human genome, called ribonucleic acid (RNA), and determine how RNA functions to orchestrate the unique patterns of protein expression seen in human tissues and in disease.
A brain circuit that works as a “brake” on binge alcohol drinking may help explain male-female differences in vulnerability to alcohol use disorders, according to a preclinical study led by scientists at Weill Cornell Medicine.
The greatly increased risk of cancer and cancer mortality with aging may be due in part to the buildup in the body of a key cancer-promoting molecule, according to new preclinical research from scientists at Weill Cornell Medicine.
Three proteins bind to chemical marks on molecular messages in cells, targeting the messages for degradation, according to researchers at Weill Cornell Medicine. The results overturn some prevailing models of how cells use chemical tags to control their genes' expression and may offer new targets for treating leukemia, which can arise when the chemical tags go awry.
